5 results about "Human herpes" patented technology

The present invention is directed to the use of antiviral agents, in particular valomaciclovir stearate and its polymorph Form A, as well as H2G (omaciclovir) to treat multiple sclerosis in combination with other agents, as well as the use of these agents to treat diseases and conditions such as chronic mononucleosis, long COVID, chronic fatigue syndrome, fibromyalgia, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, Alzheimer's disease, mesial temporal lobe seizures, Epstein-Barr-virus-linked autism, or an Epstein-Barr-virus-linked cancer.

Provided are human herpesvirus affinity ligands and related compositions including affinity resins.

The present invention relates to the field of immunotherapy, in particular to diseases associated with Epstein-Barr virus (EBV, also known as human gamma herpesvirus 4), such as cancer or post-transplant lymphoproliferative disease, in particular to adoptive T cell therapy or T cell receptor (TCR) gene therapy. The present invention provides a combination of nucleic acids encoding at least two TCR constructs or corresponding proteins or host cells, wherein each TCR construct is capable of specifically binding to its respective epitope in the context of a respective MHC I, and wherein the epitopes are derived from different antigens expressed by the same infectious agent or cancer, such as EBV antigens. The present invention further provides specific nucleic acids encoding a TCR alpha chain construct (TRA) and / or a TCR beta chain construct (TRB) of a TCR construct specific for an epitope complexed with human MHC I, wherein the epitope is an epitope of an Epstein-Barr virus protein, the TCR construct being specific for an epitope from LMP2A, LMP1 or EBNA3C. Proteins encoded by said nucleic acids, corresponding host cells, as well as pharmaceutical compositions and kits are also an object of the present invention.

Human herpesviruses can infect barrier and immune cells of the intestinal tract to cause microbiome dysbiosis and inflammation. Microbiome dysbiosis can affect the availability of nutrients required for normal brain function. Inflammation can compromise the intestinal barrier and lead to microbial translocation. Microbial translocation can cause brain infection or a mimicry auto-immune response. The embodiments restrict herpesvirus activity and injury by 1) the oral administration of exosomes containing factors to inhibit viral activity and restore homeostasis, and 2) the oral administration of recombinant bacteria that produce exosomes containing factors to inhibit viral activity and restore homeostasis. Another embodiment is the treatment of alpha-HHVs mediated intestinal dysfunction by nucleoside analogs, such as famciclovir, which may be combined with anti-viral exosome therapy.

Oligomer nucleotides, compositions, methods, kits, and uses are provided for detecting or quantifying a Human Cytomegalovirus virus 1 (CMV (human herpesvirus 5, HHV5) nucleic acid, e.g., using nucleic acid amplification and hybridization assays. Multiphase amplification of a CMV target sequence is also described. The oligomer nucleotides, compositions, methods, kits, and uses can be used to amplify and / or detect the UL56 gene of CMV.